Kaposi sarcoma associated with rituximab-based cytotoxic therapy.

Alkan, Ali; Yasar, Arzu; Toprak, Serhat

Alkan, Ali; Yasar, Arzu; Toprak, Serhat.

Afiliación

Alkan A; Department of Internal Medicine, Medical Oncology Unit, Mugla S|tk| Koçman University School of Medicine, Mugla, Turkey.
Yasar A; Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
Toprak S; Department of Pathology, Inönü University School of Medicine, Turgut Özal Medical Center, Malatya, Turkey.

J Oncol Pharm Pract ; 26(1): 220-223, 2020 Jan.

Article en En | MEDLINE | ID: mdl-30854926

RESUMEN

Kaposi sarcoma (KS) is a low-grade mesenchymal angioproliferative disease, mostly observed in immune compromised patients. KS is mostly encountered in HIV-positive or organ transplant patients. The drugs causing immunosuppression have also been associated with KS. Here, we present a KS experience associated with rituximab-based therapy.

Asunto(s)

Antineoplásicos Inmunológicos/efectos adversos; Rituximab/efectos adversos; Sarcoma de Kaposi/inducido químicamente; Anciano; Humanos; Masculino

Palabras clave

HHV-8; Kaposi sarcoma; Rituximab; lymphoma

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sarcoma de Kaposi / Rituximab / Antineoplásicos Inmunológicos Tipo de estudio: Risk_factors_studies Límite: Aged / Humans / Male Idioma: En Revista: J Oncol Pharm Pract Asunto de la revista: FARMACIA Año: 2020 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google